News

New Tool Estimates Amyloid Risk in Early Alzheimer’s

News article published on Conexiant about Cognivue's value-add component now integrated into the Cognivue Clarity tool—The Cognivue Amyloid Risk Measure (CARM)*—a cognitive performance–based score that stratifies older adults by predicting likelihood of risk of cerebral amyloid deposition.
Read more

Clinical Application and Potential of Cognitive Amyloid Risk Measure: James Galvin, MD, MPH

News article and an explanatory video published on NeurologyLive. In it, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, gives an informative explanation of the clinical application of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).*
Read more

New Metric Predicts the Likelihood of Amyloid Presence and Leads the Way in Early Alzheimer’s Detection

Novel Cognivue CARM Score Feature Now Available on Cognivue Clarity Device; Marks Milestone in Alzheimer’s Early Detection Research
May 14, 2025
Neuroscience technology innovator Cognivue®, today announced a scientific breakthrough with the launch of the Cognivue Amyloid Risk Measure (CARM)*, a novel metric that predicts the likelihood of the presence of amyloid—a key biomarker of Alzheimer’s disease (AD). Now...
Read more

Cognivue® to Partner on Another Major Clinical Study with the Global Alzheimer’s Platform Foundation

Cognivue Clarity®, a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence, will be evaluated in the Bio-Hermes-002 study.
October 30, 2024
Cognivue, Inc. announces strategic partnership with the Global Alzheimer’s Platform (GAP) as we participate in the Bio-Hermes-002 clinical trial study. As a GAP study partner, Cognivue will join Biogen and other participating...
Read more

Cognivue Names Paul W. Estes as President— Promotion of Company Veteran Reflects Neuroscience Technology Developer’s Next Evolutionary Stage

Neuroscience technology innovator Cognivue, Inc. announced today that Paul W. Estes has been promoted to president, ushering in the company’s next stage of market evolution. He will guide the executive leadership team and oversee the company’s technology roadmap planning, new product expansion, partnership relations, sales, and staffing....
Read more

Cognivue Names Dr. Ernest Fung as Vice President of Clinical and Medical Affairs

Neuroscience technology company Cognivue, Inc. has hired Ernest Fung, PsyD, ABPP, as vice president of Clinical and Medical Affairs. A distinguished clinical and forensic neuropsychologist, he brings a wealth of experience to Cognivue’s executive leadership team. Cognivue President and CEO Tom O’Neill said, “Dr. Fung’s rare blend of business and clinical experience, combined with his specialization in cognitive performance assessment and knowledge of neurodegenerative disorders as well as traumatic brain injury, will further advance Cognivue’s innovative work. We are privileged to welcome him to our veteran team...
Read more

Cognivue & DigiCARE Realized Partner to Offer Health Systems an AI-Powered Approach

ROCHESTER, N.Y. (Aug. 2, 2023)—Cognivue, Inc. and DigiCARE Realized today announced a strategic partnership to improve routine brain care across health care systems, focusing on earlier detection of Alzheimer’s disease and related dementias (ADRD). Coming on the heels of the landmark FDA approval of Leqembi, this collaboration will draw upon two transformative cognitive assessment technologies. DigiCARE Realized’s artificial...
Read more

The Kutcher Clinic Launches First-of-its-Kind Concussion Study with Cognivue®

A first-of-its-kind large-scale study conducted by the Kutcher Clinic for Sports Neurology aims to evaluate and refine how concussions are identified and treated using evidence-based diagnostic inputs. The study is funded in part by...
Read more

Cognivue Names Renowned Neuroscientist Dr. James E. Galvin as Chief Scientific Officer

ROCHESTER, NY (March 7, 2023) Renowned neuroscientist Dr. James E. Galvin has joined Cognivue as Chief Scientific Officer. He is the founding director of the Comprehensive Center for Brain Health, professor of…
Read more

Cognivue National Study Draws Remarkable 37 Percent Participation Rate of Historically Underrepresented Populations

ROCHESTER, NY (February 7, 2023) Neuroscience company Cognivue has a reported a remarkable 37 percent research participation rate of historically underserved and underrepresented populations in its national Further the Objective and Clinical…
Read more

New Tool Estimates Amyloid Risk in Early Alzheimer’s

News article published on Conexiant about Cognivue's value-add component now integrated into the Cognivue Clarity tool—The Cognivue Amyloid Risk Measure (CARM)*—a cognitive performance–based score that stratifies older adults by predicting likelihood of risk of cerebral amyloid deposition.
Read more

Clinical Application and Potential of Cognitive Amyloid Risk Measure: James Galvin, MD, MPH

News article and an explanatory video published on NeurologyLive. In it, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, gives an informative explanation of the clinical application of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).*
Read more

New Metric Predicts the Likelihood of Amyloid Presence and Leads the Way in Early Alzheimer’s Detection

Novel Cognivue CARM Score Feature Now Available on Cognivue Clarity Device; Marks Milestone in Alzheimer’s Early Detection Research
May 14, 2025
Neuroscience technology innovator Cognivue®, today announced a scientific breakthrough with the launch of the Cognivue Amyloid Risk Measure (CARM)*, a novel metric that predicts the likelihood of the presence of amyloid—a key biomarker of Alzheimer’s disease (AD). Now...
Read more

Cognivue® to Partner on Another Major Clinical Study with the Global Alzheimer’s Platform Foundation

Cognivue Clarity®, a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence, will be evaluated in the Bio-Hermes-002 study.
October 30, 2024
Cognivue, Inc. announces strategic partnership with the Global Alzheimer’s Platform (GAP) as we participate in the Bio-Hermes-002 clinical trial study. As a GAP study partner, Cognivue will join Biogen and other participating...
Read more

Cognivue Names Paul W. Estes as President— Promotion of Company Veteran Reflects Neuroscience Technology Developer’s Next Evolutionary Stage

Neuroscience technology innovator Cognivue, Inc. announced today that Paul W. Estes has been promoted to president, ushering in the company’s next stage of market evolution. He will guide the executive leadership team and oversee the company’s technology roadmap planning, new product expansion, partnership relations, sales, and staffing....
Read more

Cognivue Names Dr. Ernest Fung as Vice President of Clinical and Medical Affairs

Neuroscience technology company Cognivue, Inc. has hired Ernest Fung, PsyD, ABPP, as vice president of Clinical and Medical Affairs. A distinguished clinical and forensic neuropsychologist, he brings a wealth of experience to Cognivue’s executive leadership team. Cognivue President and CEO Tom O’Neill said, “Dr. Fung’s rare blend of business and clinical experience, combined with his specialization in cognitive performance assessment and knowledge of neurodegenerative disorders as well as traumatic brain injury, will further advance Cognivue’s innovative work. We are privileged to welcome him to our veteran team...
Read more

Cognivue & DigiCARE Realized Partner to Offer Health Systems an AI-Powered Approach

ROCHESTER, N.Y. (Aug. 2, 2023)—Cognivue, Inc. and DigiCARE Realized today announced a strategic partnership to improve routine brain care across health care systems, focusing on earlier detection of Alzheimer’s disease and related dementias (ADRD). Coming on the heels of the landmark FDA approval of Leqembi, this collaboration will draw upon two transformative cognitive assessment technologies. DigiCARE Realized’s artificial...
Read more

The Kutcher Clinic Launches First-of-its-Kind Concussion Study with Cognivue®

A first-of-its-kind large-scale study conducted by the Kutcher Clinic for Sports Neurology aims to evaluate and refine how concussions are identified and treated using evidence-based diagnostic inputs. The study is funded in part by...
Read more

Cognivue Names Renowned Neuroscientist Dr. James E. Galvin as Chief Scientific Officer

ROCHESTER, NY (March 7, 2023) Renowned neuroscientist Dr. James E. Galvin has joined Cognivue as Chief Scientific Officer. He is the founding director of the Comprehensive Center for Brain Health, professor of…
Read more

Cognivue National Study Draws Remarkable 37 Percent Participation Rate of Historically Underrepresented Populations

ROCHESTER, NY (February 7, 2023) Neuroscience company Cognivue has a reported a remarkable 37 percent research participation rate of historically underserved and underrepresented populations in its national Further the Objective and Clinical…
Read more

Schedule a Cognivue DEMO Today


Quick Links

Cognivue Clarity® Device

Cognivue Thrive® Device

Cogniwell® Lifestyle

Healthcare

Physicians

Hearing Healthcare

Pharmacy

Contact Us

585.203.1969

support@cognivue.com

7911 Rae Blvd.
Victor, NY 14564

Follow Us

  • youtube
  • linkedin
  • facebook
  • twitter
Support Customer Login

©2025 Cognivue, Inc.  |  Privacy Policy  |  References